Endpoints News

Novartis sees Avidity's platform as more than a muscular dystrophy play. endpoints.news/novartis-says-…

Recordati is in play; Sobi's gout drug passes its Phase 3 test. endpoints.news/tender-offer-f…

Another Amgen executive heads for the exit as its CFO retires; Josh Smiley is out at Zai Lab. endpoints.news/amgen-cfo-to-f…

A mid-stage flop ends Biogen and Denali's non-genetic Parkinson's program. endpoints.news/biogen-denali-…

🔬 Endpoints News is heading to ASCO. Join us Wednesday, June 3 from 11 AM–1 PM ET as we break down the readouts that matter, with Pfizer Chief Oncology Officer Jeff Legos, experts on the KRAS frontier and more. Register now: events.endpoints.news/asco26/home?re…

China's drugmakers are taking center stage at ASCO, led by Akeso's plenary readout on ivonescimab in lung cancer and closely watched data from Kelun-Biotech and SystImmune. endpoints.news/chinas-drugmak…

Incyte has signed AI R&D deals with Edison Scientific and Genesis Molecular AI, expanding an existing Genesis partnership with $80M upfront and over $1B in potential milestones. endpoints.news/incyte-signs-a…

⚡️Exclusive: The covert campaign to oust Marty Makary endpoints.news/how-a-group-of…

The next big multinational pharma company will come from China. Endpoints editor @ArmstrongDrew makes the case for Hengrui in the latest Post-Hoc. endpoints.news/the-next-big-p…

Readers: We'll be sending out our Pharma newsletter a bit later than usual today, to coincide with the lift of embargoes on data coming out of ASCO. We'll be in your inbox just after 5 p.m. ET today.

Exclusive: cAMPfield Therapeutics has raised a $180M Series A, the latest well-funded I&I startup built around licensed drug assets. endpoints.news/ii-biotech-cam…

Lilly's triple-G drug delivered the strongest data yet on obesity-only patients from a late-stage trial. endpoints.news/lillys-triple-…

Pfizer's new pneumonia vaccine beats its own Prevnar 20; Relay seeks $175M. endpoints.news/pfizers-next-g…

Fetal gene therapy is nearly here. Embryo editing is the next question. endpoints.news/fetal-gene-the…

GHO Capital and CBC Group are merging to create what could be healthcare's largest specialist investor. endpoints.news/gho-capital-cb…

Fresh off a Regeneron deal, Parabilis sets its sights on an IPO. endpoints.news/parabilis-reve…

TrumpRx is expanding its generic drug offerings more than sevenfold, adding 600-plus medicines to its direct-to-consumer pricing platform. endpoints.news/trumprx-adds-h…

Wave's RNA editing treatment for AATD aims for a monthly dosing edge. endpoints.news/wave-aims-for-…

Q&A: Novo Nordisk's research chief breaks down its R&D overhaul — and where AI fits in. endpoints.news/qa-novo-resear…

BioMarin's therapy for a rare bone disorder raised a key biomarker in Phase 3 but failed to show clinical benefit. endpoints.news/biomarins-rare…